{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/143444734"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ " when to approve Pfizer's drug applications as well as their decisions regarding labeling, ingredients and other matters that could affect the availability or commercial potential of Pfizer's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success of external business-development activities; competitive developments, including t" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "prnewswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/256269558"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/143444734"] } } }
